The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers
Abstract
BACKGROUND: Despite the relative success of opiate antagonist medication within controlled clinical trials for alcoholism, laboratory studies have not fully examined potential mechanisms for their efficacy in alcohol-dependent persons. The present study evaluated the impact of naltrexone and nalmefene on craving and subjective effects after a moderate alcohol dose among non-treatment-seeking alcoholics (n = 125) and social drinkers (n = 90). METHODS: Participants were randomly assigned to receive placebo, naltrexone (titrated to 50 mg/day), or nalmefene (titrated to 40 mg/day) for seven days before an alcohol challenge clinical laboratory session. During the clinical laboratory session, a drink of alcohol (0.4 mg/kg for men, 0.34 mg/kg for women) was provided in a bar-like setting. The effects of the alcohol dose on subjective craving, stimulation, and sedation were measured before having free access to alcohol. RESULTS: Alcoholics reported higher levels of craving than social drinkers before and after the drink as well as higher levels of alcohol-induced stimulation. Both opiate antagonist medications suppressed initial increases in craving and stimulation. CONCLUSIONS: These findings demonstrate that both naltrexone and nalmefene are associated with reduced alcohol-induced craving and stimulation among alcoholics who are not actively attempting to reduce drinking. These data provide insights into potential mechanisms that may underlie opiate antagonists' effects in the context of treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The findings may have relevance to medication development, as altering euphoric and pleasurable effects of alcohol would be important targets for novel treatments and are hypothesized to underlie in part the efficacy of opioid receptor antagonists, including naltrexone and nalmefene(67–76).”
From A Prospective 5-Year Re-examination of Alcohol Response in Heavy Drinkers Progressing in Alcohol Use Disorder (2016) · cites this paper as [68]
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
An inventory for measuring clinical anxiety: Psychometric properties.
Beck, A. T., Epstein, N., Brown, G., & Steer, R. A. (1988) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.56.6.893 · Cited by 14,407
The neural basis of drug craving: An incentive-sensitization theory of addiction
Robinson, T. (1993) · Brain Research Reviews · doi:10.1016/0165-0173(93)90013-p · Cited by 7,346
Depression. Clinical, Experimental, and Theoretical Aspects.
(1968) · Annals of Internal Medicine · doi:10.7326/0003-4819-68-2-502 · Cited by 5,233
Sobell, L. C., & Sobell, M. B. (1992) · Measuring Alcohol Consumption · doi:10.1007/978-1-4612-0357-5_3 · Cited by 4,110
SULLIVAN, J. T., SYKORA, K., SCHNEIDERMAN, J., NARANJO, C. A., & SELLERS, E. M. (1989) · British Journal of Addiction · doi:10.1111/j.1360-0443.1989.tb00737.x · Cited by 1,988
The Family History Method Using Diagnostic Criteria
Andreasen, N. C. (1977) · Archives of General Psychiatry · doi:10.1001/archpsyc.1977.01770220111013 · Cited by 1,903
Naltrexone in the Treatment of Alcohol Dependence
Volpicelli, J. R. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110040006 · Cited by 1,828
Naltrexone and Coping Skills Therapy for Alcohol Dependence
O’Malley, S. S. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110045007 · Cited by 1,476
Frezza, M., di Padova, C., Pozzato, G., Terpin, M., Baraona, E., & Lieber, C. S. (1990) · New England Journal of Medicine · doi:10.1056/nejm199001113220205 · Cited by 1,328
Research works printed but not linked: 3
- FirstMB SpitzerRL GibbonM WilliamsJBW(1994)Structured Clinical Interview for Axis I DSM‐IV Disorders—Patient Edition (SCID‐I/P version 2.0).Biometrics Research Department New York State Psychiatric Institute.
- National Advisory Council on Alcohol Abuse and Alcoholism, 1988, Recommended Council Guidelines on Ethyl Alcohol Administration in Human Experimentation
- Singleton EG, 1999, Alcohol Craving Questionnaire (ACQ‐NOW): Background, Scoring, and Administration
Cited by
Sorted by citations
Opioid antagonists for alcohol dependence
Srisurapanont, M., & Jarusuraisin, N. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001867 · Cited by 762
Alcoholism: A Systems Approach From Molecular Physiology to Addictive Behavior
Spanagel, R. (2009) · Physiological Reviews · doi:10.1152/physrev.00013.2008 · Cited by 658
Volkow, N. D., & Blanco, C. (2023) · World psychiatry · doi:10.1002/wps.21073 · Cited by 503
Lingford-Hughes, A., Welch, S., Peters, L., Nutt, D., & With expert reviewers (in alphabetical order): Ball D, B. N. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444324 · Cited by 332
Ray, L. A., & Hutchison, K. E. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.9.1069 · Cited by 258
Opioid antagonists for alcohol dependence
Rösner, S., Hackl-Herrwerth, A., Leucht, S., Vecchi, S., Srisurapanont, M., & Soyka, M. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001867.pub3 · Cited by 255
Subjective Response to Alcohol: A Critical Review of the Literature
Morean, M. E., & Corbin, W. R. (2009) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2009.01103.x · Cited by 224
Filbey, F. M., Ray, L. A., Smolen, A., Claus, E. D., Audette, A., & Hutchison, K. E. (2008) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2008.00692.x · Cited by 195
Anton, R. F., Latham, P., Voronin, K., Book, S., Hoffman, M., Prisciandaro, J., & Bristol, E. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.0249 · Cited by 186
Naltrexone for the Management of Alcohol Dependence
Anton, R. F. (2008) · New England Journal of Medicine · doi:10.1056/nejmct0801733 · Cited by 184
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder
Burnette, E. M., Nieto, S. J., Grodin, E. N., Meredith, L. R., Hurley, B., Miotto, K., Gillis, A. J., & Ray, L. A. (2022) · Drugs · doi:10.1007/s40265-021-01670-3 · Cited by 169
State-of-the-art behavioral and pharmacological treatments for alcohol use disorder
Ray, L. A., Bujarski, S., Grodin, E. N., Hartwell, E. E., Green, R., Venegas, A., Lim, A. C., Gillis, A. J., & Miotto, K. A. (2018) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2018.1528265 · Cited by 136
Tidey, J. W., Monti, P. M., Rohsenow, D. J., Gwaltney, C. J., Miranda, R., McGeary, J. E., MacKillop, J. M., Swift, R. M., Abrams, D. B., Shiffman, S. M., et al. (2007) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2007.00545.x · Cited by 137
King, A. C., Hasin, D., O’Connor, S. J., McNamara, P. J., & Cao, D. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.05.007 · Cited by 132
Ray, L. A., MacKillop, J., & Monti, P. M. (2010) · Substance Use & Misuse · doi:10.3109/10826084.2010.482427 · Cited by 132
Oslin, D. W., Cary, M. S., Slaymaker, V., Colleran, C., & Blow, F. C. (2009) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.03.009 · Cited by 132
Ray, L. A., Miranda, R., Tidey, J. W., McGeary, J. E., MacKillop, J. M., Gwaltney, C. J., Rohsenow, D. J., Swift, R. M., & Monti, P. M. (2010) · Journal of Abnormal Psychology · doi:10.1037/a0017550 · Cited by 126
Miranda, R., MacKillop, J. M., Monti, P. M., Rohsenow, D. J., Tidey, J. W., Gwaltney, C. J., Swift, R. M., Ray, L. A., & McGeary, J. E. (2008) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2007.00592.x · Cited by 115
Genetic Moderators of Naltrexone's Effects on Alcohol Cue Reactivity
McGeary, J. E., Monti, P. M., Rohsenow, D. J., Tidey, J. W., Swift, R. M., & Miranda, R. (2006) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2006.00156.x · Cited by 105
Miranda, R., Ray, L. A., Blanchard, A., Reynolds, E. K., Monti, P. M., Chun, T. H., Justus, A. N., Swift, R. M., Tidey, J. W., Gwaltney, C. J., et al. (2013) · Addiction Biology · doi:10.1111/adb.12050 · Cited by 102
Hendershot, C. S., Wardell, J. D., Samokhvalov, A. V., & Rehm, J. T. (2016) · Addiction Biology · doi:10.1111/adb.12425 · Cited by 96
Schacht, J. P., Anton, R. F., Voronin, K. E., Randall, P. K., Li, X., Henderson, S., & Myrick, H. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.195 · Cited by 88
Endogenous opiates and behavior: 2004
Bodnar, R. J., & Klein, G. E. (2005) · Peptides · doi:10.1016/j.peptides.2005.06.010 · Cited by 86
The role of the opioid system in alcohol dependence
Nutt, D. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113504017 · Cited by 87
Acute Interaction of Baclofen in Combination With Alcohol in Heavy Social Drinkers
Evans, S. M., & Bisaga, A. M. (2008) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2008.00805.x · Cited by 84
Lukas, S. E., Lowen, S. B., Lindsey, K. P., Conn, N., Tartarini, W., Rodolico, J., Mallya, G., Palmer, C., & Penetar, D. M. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2013.03.055 · Cited by 83
Prolonged Central μ-Opioid Receptor Occupancy after Single and Repeated Nalmefene Dosing
Ingman, K., Hagelberg, N. M., Aalto, S., Någren, K., Juhakoski, A., Karhuvaara, S., Kallio, A., Oikonen, V., Hietala, J. A., & Scheinin, H. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300790 · Cited by 83
Review article: pharmacotherapy for alcohol dependence – the why, the what and the wherefore
Goh, E. T., & Morgan, M. Y. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13965 · Cited by 73
Effects of Opioid Receptor Gene Variation on Targeted Nalmefene Treatment in Heavy Drinkers
Arias, A. J., Armeli, S., Gelernter, J. E., Covault, J., Kallio, A., Karhuvaara, S., Koivisto, T., Mäkelä, R., & Kranzler, H. R. (2008) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2008.00735.x · Cited by 71
Pharmacogenetics of Naltrexone in Asian Americans: A Randomized Placebo-Controlled Laboratory Study
Ray, L. A., Bujarski, S., Chin, P. F., & Miotto, K. A. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.192 · Cited by 71
The effects of drinking goal on treatment outcome for alcoholism.
Bujarski, S., O’Malley, S. S., Lunny, K. F., & Ray, L. A. (2012) · Journal of Consulting and Clinical Psychology · doi:10.1037/a0030886 · Cited by 70
Subjective Response to Alcohol as a Research Domain Criterion
Ray, L. A., Bujarski, S., & Roche, D. J. O. (2016) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.12927 · Cited by 75
Timäus, C., Meiser, M., Bandelow, B., Engel, K., Paschke, A. M., Wiltfang, J., & Wedekind, D. (2019) · BMC Psychiatry · doi:10.1186/s12888-019-2377-z · Cited by 68
Targeted Opioid Receptor Antagonists in the Treatment of Alcohol Use Disorders
Niciu, M. J., & Arias, A. J. (2013) · CNS Drugs · doi:10.1007/s40263-013-0096-4 · Cited by 74
Bujarski, S., MacKillop, J. M., & Ray, L. A. (2012) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0027379 · Cited by 69
Voronin, K. E., Randall, P. K., Myrick, H., & Anton, R. F. (2008) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2008.00783.x · Cited by 67
Yardley, M. M., & Ray, L. A. (2016) · Addiction Biology · doi:10.1111/adb.12349 · Cited by 62
Ray, L. A., Green, R., Roche, D. J. O., Magill, M., & Bujarski, S. (2019) · Addiction Biology · doi:10.1111/adb.12747 · Cited by 65
Ashenhurst, J. R., Bujarski, S., & Ray, L. A. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.08.019 · Cited by 57
Alcohol use disorder: pathophysiology, effects, and pharmacologic options for treatment
Clapp, P., Wackernah, R. C., & Minnick, M. (2014) · Substance Abuse and Rehabilitation · doi:10.2147/sar.s37907 · Cited by 58
Treatment-refractory substance use disorder: focus on alcohol, opioids, and cocaine
Soyka, M., & Mutschler, J. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.11.003 · Cited by 49
Application of Human Laboratory Models to Pharmacotherapy Development for Alcohol Dependence
Ray, L. A., Hutchison, K. E., & Tartter, M. A. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791516422 · Cited by 46
Ray, L. A., Miranda, R., Kahler, C. W., Leventhal, A. M., Monti, P. M., Swift, R. M., & Hutchison, K. E. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0794-z · Cited by 43
Nalmefene for the treatment of alcohol dependence: a current update
Soyka, M. (2013) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713001284 · Cited by 42
Bauer, I. E., Soares, J. C., & Nielsen, D. A. (2014) · American Journal on Addictions · doi:10.1111/ajad.12172 · Cited by 42
Williams, K. L., & Broadbridge, C. L. (2009) · Alcohol · doi:10.1016/j.alcohol.2008.11.003 · Cited by 39
Stimulant and motivational effects of alcohol: Lessons from rodent and primate models
Brabant, C., Guarnieri, D. J., & Quertemont, É. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2014.03.006 · Cited by 42
Possible role of a dysregulation of the endogenous opioid system in antisocial personality disorder
Bandelow, B., & Wedekind, D. (2015) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2497 · Cited by 38
Opioid modulators for alcohol dependence
Hillemacher, T., Heberlein, A., Muschler, M. A. N., Bleich, S., & Frieling, H. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.592139 · Cited by 39
Nalmefene for the treatment of alcohol use disorders: recent data and clinical potential
Soyka, M. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1146689 · Cited by 37
Development of medications for alcohol use disorders: recent advances and ongoing challenges
Litten, R. Z., Fertig, J. B., Mattson, M. E., & Egli, M. (2005) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.10.2.323 · Cited by 36
Schick, M. R., Spillane, N. S., & Hostetler, K. L. (2020) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.14440 · Cited by 33
Bujarski, S., & Ray, L. A. (2016) · Behaviour Research and Therapy · doi:10.1016/j.brat.2016.05.008 · Cited by 37
Pharmacogenetics of Addiction Therapy
Nielsen, D. A., Nielsen, E. M., Dasari, T., & Spellicy, C. J. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-0956-8_15 · Cited by 32
Porchet, R. I., Boekhoudt, L., Studer, B., Gandamaneni, P. K., Rani, N., Binnamangala, S., Müller, U., & Clark, L. (2013) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2013.00138 · Cited by 31
Advances in Pharmacotherapy Development: Human Clinical Studies
Litten, R. Z., Falk, D. E., Ryan, M. L., Fertig, J. B., & Leggio, L. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_79 · Cited by 29
Effects of Naltrexone During the Descending Limb of the Blood Alcohol Curve
Ray, L. A., Hutchison, K. E., MacKillop, J. M., Miranda, R., Audette, A., Swift, R. M., & Monti, P. M. (2008) · American Journal on Addictions · doi:10.1080/10550490802138400 · Cited by 28
Plawecki, M. H., DeCarlo, R. A., Ramchandani, V. A., & O’Connor, S. (2007) · Biomedical Signal Processing and Control · doi:10.1016/j.bspc.2007.04.001 · Cited by 27
McHardy, S. F., Heck, S. D., Guediche, S., Kalman, M., Allen, M. P., Tu, M., Bryce, D. K., Schmidt, A. W., Vanase-Frawley, M. A., Callegari, E., et al. (2011) · MedChemComm · doi:10.1039/c1md00164g · Cited by 26
Nalmefene for treatment of alcohol dependence
Soyka, M., & Rösner, S. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.522990 · Cited by 26
Ray, L. A., Hutchison, K. E., Ashenhurst, J. R., & Morrow, A. L. (2010) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2010.01233.x · Cited by 24
Human pharmacology for addiction medicine
Quednow, B. B., & Herdener, M. (2015) · Progress in brain research · doi:10.1016/bs.pbr.2015.07.017 · Cited by 27
McCaul, M. E., Wand, G. S., Weerts, E. M., & Xu, X. (2018) · Addiction Biology · doi:10.1111/adb.12511 · Cited by 23
Antonelli, M., Sestito, L., Tarli, C., & Addolorato, G. (2022) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2022.05.016 · Cited by 23
Quetiapine for the treatment of alcoholism: Scientific rationale and review of the literature
Ray, L. A., Heydari, A., & Zorick, T. S. (2010) · Drug and Alcohol Review · doi:10.1111/j.1465-3362.2010.00185.x · Cited by 24
Impulsivity Moderates Subjective Responses to Alcohol in Alcohol-Dependent Individuals
Westman, J. G., Bujarski, S., & Ray, L. A. (2016) · Alcohol and Alcoholism · doi:10.1093/alcalc/agw096 · Cited by 22
Effects of naltrexone on cortisol levels in heavy drinkers
Ray, L. A., MacKillop, J. M., Leggio, L., Morgan, M., & Hutchison, K. E. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.09.004 · Cited by 23
The effects of naltrexone among alcohol non-abstainers: results from the COMBINE study
Ray, L. (2010) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2010.00026 · Cited by 21
Alcohol Use and Alcohol Use Disorders
Sher, K. J., Talley, A. E., Littlefield, A. K., & Martinez, J. A. (2012) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780195342819.013.0028 · Cited by 22
Swimmer, K. R., & Sandelich, S. (2023) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2023.06.023 · Cited by 20
Sawicka, M., & Tracy, D. K. (2017) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125317709975 · Cited by 20
Nieto, S. J., Quave, C. B., & Kosten, T. A. (2018) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2018.02.003 · Cited by 21
Naloxone blocks ethanol-mediated appetitive conditioning and locomotor activation in adolescent rats
Pautassi, R. M., Nizhnikov, M. E., Acevedo, M. B., & Spear, N. E. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.08.005 · Cited by 19
Calleja‐Conde, J., Echeverry‐Alzate, V., Giné, E., Bühler, K., Nadal, R. A., Maldonado, R. J., de Fonseca, F. R., Gual, A., & López‐Moreno, J. A. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13526 · Cited by 18
Ray, L., Green, R., Roche, D. J. O., Bujarski, S., Hartwell, E., Lim, A. C., Rohrbaugh, T., Ghahremani, D., Hutchison, K., & Miotto, K. (2018) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.13586 · Cited by 17
Drug adjuncts for treating alcohol dependence.
Collins, G. B., McAllister, M. S., & Adury, K. (2006) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.73.7.641 · Cited by 17
Drinking Levels and Profiles of Alcohol Addicted Rats Predict Response to Nalmefene
Foo, J. C., Vengeliene, V., Noori, H. R., Yamaguchi, I., Morita, K., Nakamura, T., Yamamoto, Y., & Spanagel, R. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00471 · Cited by 17
Edinoff, A. N., Nix, C. A., Reed, T. D., Bozner, E. M., Alvarez, M. R., Fuller, M. C., Anwar, F., Cornett, E. M., Kaye, A. M., & Kaye, A. D. (2021) · Psychiatry International · doi:10.3390/psychiatryint2040028 · Cited by 17
Efficacy of naltrexone in borderline personality disorder, a retrospective analysis in inpatients
Timäus, C., Meiser, M., Wiltfang, J., Bandelow, B., & Wedekind, D. (2021) · Human psychopharmacology · doi:10.1002/hup.2800 · Cited by 11
Johansen, K. G. V., Tarp, S., Astrup, A. V., Lund, H., Pagsberg, A. K., & Christensen, R. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183821 · Cited by 16
Integrative Pharmacology in the Treatment of Substance Use Disorders
Donlon, J., Kumari, P., Varghese, S. P., Bai, M. Y., Florentin, O. D., Frost, E. D., Banks, J., Vadlapatla, N., Kam, O., Shad, M. U., et al. (2023) · Journal of Dual Diagnosis · doi:10.1080/15504263.2023.2293854 · Cited by 15
Los Antagonistas de los Receptores Opioides en el Tratamiento del Alcoholismo
Serecigni, J. G. (2015) · Adicciones · doi:10.20882/adicciones.708 · Cited by 14
Lipophilic nalmefene prodrugs to achieve a one-month sustained release
Gaekens, T., Guillaume, M., Borghys, H., de Zwart, L. L., de Vries, R., Embrechts, R. C. A., Vermeulen, A., Megens, A. A. H. P., Leysen, J. E., Herdewijn, P. A., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.04.029 · Cited by 14
Endpoints for Pharmacotherapy Trials for Alcohol Use Disorder
Belnap, M. A., McManus, K. R., Grodin, E. N., & Ray, L. A. (2024) · Pharmaceutical Medicine · doi:10.1007/s40290-024-00526-x · Cited by 13
Armeli, S., Feinn, R., Tennen, H. A., & Kranzler, H. R. (2006) · Experimental and Clinical Psychopharmacology · doi:10.1037/1064-1297.14.2.199 · Cited by 13
Ooteman, W., Verheul, R., Naassïla, M., Daoust, M., Schippers, G. M., Koeter, M. W. J., & van den Brink, W. (2005) · Journal of Substance Use · doi:10.1080/14659890500038764 · Cited by 14
Subjective Response as a Consideration in the Pharmacogenetics of Alcoholism Treatment
Roche, D. J., & Ray, L. A. (2015) · Pharmacogenomics · doi:10.2217/pgs.14.143 · Cited by 13
Tarli, C., Mirijello, A., & Addolorato, G. (2022) · Seminars in Liver Disease · doi:10.1055/a-1798-2872 · Cited by 12
Cambio de paradigma en el tratamiento del alcoholismo de baja gravedad
Serecigni, J. G. (2011) · Adicciones · doi:10.20882/adicciones.126 · Cited by 9
Modern pharmacotherapy guidance for treating alcohol use disorders
Soyka, M., & Rösner, S. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2445734 · Cited by 11
Waddell, J. T., Corbin, W. R., MacKinnon, D. P., Leeman, R. F., DeMartini, K. S., Fucito, L. M., Kranzler, H. R., & O’Malley, S. S. (2022) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.14780 · Cited by 10
Pharmacotherapy for alcohol dependence: A stratified approach
Thompson, A., Owens, L., Pushpakom, S. P., Faizal, M. A., & Pirmohamed, M. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.05.010 · Cited by 10
Neural Basis of Pleasure and Reward
Knapp, C. M., & Kornetsky, C. H. (2009) · Wiley eBooks · doi:10.1002/9780470478509.neubb002040 · Cited by 9
Alcohol Stimulation and Sedation: a Critical Review of the Biphasic Alcohol Effects Scale
Boyd, S. J., Corbin, W. R., Morean, M. E., & Martin, C. S. (2017) · Current Addiction Reports · doi:10.1007/s40429-017-0150-2 · Cited by 8
Pharmakologische Rückfallprävention bei Alkohol- und Tabakabhängigkeit
Diehl, A., & Mann, K. F. (2006) · Der Internist · doi:10.1007/s00108-006-1755-z · Cited by 8
Neuroendocrine effects of naltrexone versus nalmefene in humans
Butelman, E. R., Fry, R. S., Kimani, R. W., Reed, B., & Kreek, M. J. (2020) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2726 · Cited by 7
Smith, R. C., Feldner, M. T., & Badour, C. L. (2011) · Journal of Experimental Psychopathology · doi:10.5127/jep.011310 · Cited by 7
Sodium oxybate plus nalmefene for the treatment of alcohol use disorder: A case series
Caputo, F., Maremmani, A. G. I., Addolorato, G., Domenicali, M., Zoli, G., d’Amore, A., Maremmani, I., & Bernardi, M. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116629126 · Cited by 8
Stasiak, A., & Fogel, W. A. (2008) · PubMed · Cited by 6
Pharmacogenetics of Addiction Therapy
Graham, D. P., Harding, M. J., & Nielsen, D. A. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2573-6_16 · Cited by 6
Metadata
- Authors
- Drobes, D. J., Anton, R. F., Thomas, S. E., & Voronin, K.
- Affiliations
- Medical University of South Carolina (US)
- Corresponding author
- Drobes, David J.
- Venue
- Alcoholism Clinical and Experimental Research
- Publisher
- Wiley
- Published
- 2004-09
- Volume
- 28
- Issue
- 9
- Pages
- 1362-1370
- ISSN
- 0145-6008 (ISSN-L)
- 1530-0277
- OpenAlex
- W2032321294
- Cited by
- 140
- References
- 47
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 7 · 2022: 5 · 2021: 4 · 2020: 4 · 2019: 6 · 2018: 5 · 2017: 9 · 2016: 10 · 2015: 16 · 2014: 7 · 2013: 8 · 2012: 8
- FWCI
- 3.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Alcoholism Clinical and Experimental Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Alcohol Abuse and Alcoholism (P50AA010761)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- naltrexone, nalmefene, opioid antagonists, alcohol craving, subjective effects of alcohol, alcoholism, social drinkers
- MeSH terms
- Adult, Aged, Alcohol Drinking, Alcoholism, Analysis of Variance, Female, Humans, Male, Middle Aged, Naltrexone, Behavior, Addictive
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
